PLEKHH2

Across TCGA pan-cancer cohorts, PLEKHH2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLEKHH2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLEKHH2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLEKHH2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where PLEKHH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.783	0.207	.032	7	view →
LSCC	OS	Median	All	0.921	1.000	.011	6	view →
PDAC	OS	Median	III,IV	0.799	0.144	.024	6	view →
CCRCC	DFS	Median	All	0.403	1.000	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLEKHH2–LUAD (DFS)

Open the LUAD breakdown →